BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or BPC 157 Dosing (Common Protocols) Oral Subcutaneous 500 mcg daily Duration: 6 weeks Intramuscular Peritendinous 1 mg daily Duration: 6 weeks Note: Not approved BPC 157: Science Backed Uses, Benefits, Dosage, and Safety BPC 157 Benefits and Research Applications Presentation of the rat retina after retrobulbar administered L NAME Download Scientific Diagram A new pilot study administered BPC 157 intravenously at doses 2040 higher than what's typically used in biohacking circles 10 mg on day one and 20 mg on day two. To put